{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:06:27Z","timestamp":1791950787270,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T00:00:00Z","timestamp":1210204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p>The present study characterizes the safety, pharmacokinetics, and anti\u2010emetic effects of the selective NK\u20101 receptor antagonist maropitant in the cat. Safety of maropitant was determined following 15\u2003days of subcutaneous (SC) administration at 0.5\u20135\u2003mg\/kg. Maropitant was well tolerated in cats at doses that exceeded the efficacious anti\u2010emetic dose range of the drug by at least a factor of 10 and adverse clinical signs or pathological safety findings were not noted at any dose.The pharmacokinetics of maropitant in cats were determined following single dose oral (PO), intravenous (IV) and SC administration. Maropitant had a terminal half\u2010life of 13\u201317\u2003h and a bioavailability of 50 and 117% when administered PO and SC, respectively. Efficacy was determined against emesis induced either by xylazine or by motion. A dosage of 1\u2003mg\/kg maropitant administered IV, SC or PO prevented emesis elicited by xylazine. The compound had good oral antiemetic activity and a long (24\u2003h) duration of action. Maropitant (1.0\u2003mg\/kg) was highly effective in preventing motion\u2010induced emesis in cats. These studies indicate that the NK\u20101 receptor antagonist maropitant is well tolerated, safe and has excellent anti\u2010emetic properties in cats.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2008.00952.x","type":"journal-article","created":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T13:36:02Z","timestamp":1210253762000},"page":"220-229","source":"Crossref","is-referenced-by-count":102,"title":["Safety, pharmacokinetics and use of the novel NK\u20101 receptor antagonist maropitant (Cerenia\n                    <sup>TM<\/sup>\n                    ) for the prevention of emesis and motion sickness in cats"],"prefix":"10.1111","volume":"31","author":[{"given":"M. A.","family":"HICKMAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"COX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"MAHABIR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"MISKELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"LIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"BUNGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"McCALL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,5,8]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(93)90189-A"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01113-7"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00877.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.161.13.444"},{"key":"e_1_2_5_6_1","first-page":"239","volume-title":"Mechanisms and Control of Emesis","author":"Bhandari P.","year":"1992"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90673-6"},{"key":"e_1_2_5_8_1","first-page":"9","volume-title":"Motion and Space Sickness","author":"Brizzee K.R.","year":"1990"},{"key":"e_1_2_5_9_1","first-page":"462","article-title":"A stimulator for laboratory studies of motion sickness in cats","volume":"56","author":"Crampton G.H.","year":"1985","journal-title":"Aviation Space and Environmental Medicine"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2006.00321.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.68.1.48"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00847.x"},{"key":"e_1_2_5_13_1","first-page":"516P","article-title":"Anti\u2010emetic activity of neurokinin NK receptor antagonists is mediated centrally in the ferret","volume":"112","author":"Gardner C.J.","year":"1994","journal-title":"British Journal of Pharmacology"},{"issue":"11","key":"e_1_2_5_14_1","first-page":"18","article-title":"Imaging substance P receptors (NK\u20101) in the living human brain using positron emission tomography","volume":"63","author":"Hargreaves R.","year":"2002","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90235-9"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700888"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199607)16:4<297::AID-MED1>3.0.CO;2-S"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.14-02-00871.1994"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91325-0"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.12.2279"},{"key":"e_1_2_5_21_1","article-title":"Efficacy and safety of maropitant (CereniaTM) an NK\u20101 antagonist for preventing motion sickness in dogs","author":"Ramsey D.S.","year":"2008","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(99)01396-6"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00259-9"},{"key":"e_1_2_5_24_1","volume-title":"The Merck Veterinary Manual","author":"Kahn C.M.","year":"2005"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2006.00123.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1931.sp002763"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16324.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/014556130608500110"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2008.00952.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2008.00952.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:10:31Z","timestamp":1697267431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2008.00952.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,8]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1365-2885.2008.00952.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2008.00952.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,8]]}}}